Ax-8 is under clinical development by Axalbion and currently in Phase II for Chronic Cough. According to GlobalData, Phase II drugs for Chronic Cough does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ax-8 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ax-8 overview

Ax-8 is under development for the treatment of chronic cough.The therapeutic candidate is administered by oromucosal, and topical route. It targets transient receptor potential cation channel subfamily M member 8 (TRPM8). The drug candidate is developed based on TRPM8 technology.

It was also under development for the treatment of inflammatory bowel disease, pruritus, and NERD(non-erosive reflux disease).

For a complete picture of Ax-8’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.